HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 6,745-6,756 of 27,277
Drug study icon
CompletedNCT01606254

Safety study of paliperidone Palmitate in schizophrenia

Official study title

A Repeated Dose Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

In Ichikawa
SchizophreniaMedication studyAges 20–65
Countries
Japan
Sponsor
Janssen Pharmaceutical K.K.
Drug study icon
CompletedNCT00986128

A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolarity Patients

Official study title

A Comparative Study of the Steady State Pharmacokinetics of Lithium Before and During Multiple Oral Daily Topiramate (RWJ-17021) Dosing in Patients With Bipolar Disorders

This study has finished and is no longer accepting participants.

Location not clearly listed
BipolarityMedication studyAges 18–60
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT01626859

A Pharmacokinetic Study of MP-214 in people with Schizophrenia

Official study title

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)

This study has finished and is no longer accepting participants.

In Sakai
SchizophreniaMedication studyAges 20–64
Countries
Japan
Sponsor
Tanabe Pharma Corporation
Drug study icon
CompletedNCT00986336

Risperidone and Topiramate Administered Alone and for schizophrenia

Official study title

A Comparative Study of the Steady-state Pharmacokinetics of Risperidone and Topiramate on Monotherapy and During Combination Therapy in Patients With Bipolar or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

Location not clearly listed
Bipolarity, SchizophreniaMedication studyAges 18–55
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00791193

A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR

Official study title

Pharmacokinetic Evaluation of the Relative Bioavailability of Three Paliperidone Extended Release (ER) Formulations With Different in Vitro Release Profiles, and Comparison to Paliperidone Immediate Release (IR), in Healthy Male Subjects

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–55
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.